株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

代謝関連の各種提携契約:契約条件・合意内容

Global Metabolic Partnering 2010-2016: Deal trends, players and financials

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 250301
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。
Back to Top
代謝関連の各種提携契約:契約条件・合意内容 Global Metabolic Partnering 2010-2016: Deal trends, players and financials
出版日: 2016年09月01日 ページ情報: 英文
概要

当レポートでは、2007年以降の代謝関連の各種提携契約について調査分析し、近年における各種契約の動向、大規模契約および大手医薬品事業者による契約の概要、契約区分・開発ステージ・技術区分・適応症区分別のディレクトリなどをまとめ、概略下記の構成でお届けいたします。

エグゼクティブサマリー

第1章 イントロダクション

第2章 代謝関連の各種契約の動向

  • イントロダクション
  • 過去数年における代謝関連の提携
  • 大手製薬会社による契約活動
  • 代謝関連の事業に積極的でない大手製薬会社
  • 代謝関連の提携:契約タイプ別
  • 代謝関連の提携:産業部門別
  • 代謝関連の提携:開発ステージ別
  • 代謝関連の提携:技術タイプ別
  • 平均契約期間

第3章 主要契約

  • イントロダクション
  • 主要契約:取引額別
  • 大手製薬会社のかかわる主要契約

第4章 大手製薬会社による契約

  • イントロダクション
  • 大手製薬会社による提携契約の利用法
  • 企業プロファイル

第5章 契約ディレクトリ

  • イントロダクション
  • 契約タイプ別
    • 資産購入
    • 譲渡
    • 大手によるアウトライセンシング
    • 共同開発
    • 共同R&D
    • 共同販売
    • サービス契約
    • 共同プロモーション
    • CRADA
    • クロスライセンス
    • 開発
    • 流通
    • 株式購入
    • ライセンシング
    • 訴訟
    • ローン
    • 製造
    • マーケティング
    • 材料転移
    • オプション
    • プロモーション
    • 研究
    • ロイヤルティ資金
    • 和解関連
    • スピンアウト
    • サブライセンス
    • 供給
    • 技術移転
    • 終了
  • 開発ステージ別
    • 創薬
    • 製剤
    • フェーズI
    • フェーズII
    • フェーズIII
    • 前臨床
    • 規制
    • 製剤
  • 技術タイプ別
    • 解析
    • 動物モデル
    • アッセイ
    • 生物学的化合物
    • バイオマーカー
    • バイオマテリアル
    • 血液製剤
    • 細胞培養
    • 細胞治療
    • 臨床検査
    • デバイス
    • 診断
    • 創薬ツール
    • DNAプローブ
    • ドラッグデリバリー
    • イネーブリング技術
    • 設備
    • 遺伝子治療
    • ゲノミクス
    • イメージング
    • インプラント
    • インビトロモデル
    • マイクロアレイ
    • ナノテクノロジー
    • 天然製品
    • オリゴヌクレオチド
    • 希少薬
    • パッケージング
    • ペプチド
    • 加工
    • プロテオミクス
    • 放射性/化学治療
    • 組み換えDNA
    • 再生医療
    • 研究サービス
    • 研究サプライ
    • RNA治療
    • スクリーニング
    • 小分子
    • 幹細胞
    • 毒性
    • ワクチン

第6章 代謝関連の契約:適応症別

  • 代謝
  • 末端肥大症
  • アジゾン病
  • 肝硬変
  • クッシング症候群
  • 糖尿病
  • 脂肪肝
  • 胆石
  • 成長ホルモン疾患
  • 甲状腺機能亢進症
  • 性腺機能低下症
  • 甲状腺機能低下症
  • フェニルケトン尿症
  • 肝臓病
  • リソソーム蓄積症
  • 栄養素・ビタミン
  • 小人症
  • 抗利尿ホルモン不適合分泌症候群(SIADH)
  • 甲状腺疾患

第7章 提携機会

  • オンラインパートナリング
  • パートナリングイベント
  • 関連資料

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP2205

‘Global Metabolic Partnering 2010-2016: Deal trends, players and financials report’ provides comprehensive understanding and unprecedented access to the metabolic partnering deals and agreements entered into by the worlds leading healthcare companies

‘Global Metabolic Partnering 2010 to 2016’ provides the full collection of Metabolic disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

  • Trends in Metabolic partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Metabolic partnering agreement structure
  • Metabolic partnering contract documents
  • Top Metabolic deals by value
  • Most active Metabolic dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Metabolic disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Metabolic deals.

The report presents financial deal terms values for Metabolic deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Metabolic dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Metabolic dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Metabolic deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Metabolic dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Metabolic deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Metabolic partnering deals by specific Metabolic target announced since 2010. The chapter is organized by specific Metabolic therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Metabolic partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Metabolic partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Metabolic technologies and products.

Report scope

‘Global Metabolic Partnering 2010 to 2016’ is intended to provide the reader with an in-depth understanding and access to Metabolic trends and structure of deals entered into by leading companies worldwide.

‘Global Metabolic Partnering 2010 to 2016’ includes:

  • Trends in Metabolic dealmaking in the biopharma industry since 2010
  • Analysis of Metabolic deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Metabolic deal contract documents
  • Comprehensive access to over 3500 Metabolic deal records
  • The leading Metabolic deals by value since 2010
  • Most active Metabolic dealmakers since 2010

The report includes deals for the following indications: Acromegaly, Addison's disease, Cirrhosis, Cushing's syndrome, Diabetes, Type 1, Type 2, Insipidus, Fatty liver, Gallstones, Goitre, Growth hormone disorders, Gynaecomastia, Inborn errors of metabolism, Phenylketonuria, Hyperaldosteronism, Hypercalcaemia, Hyperthyroidism, Hypocalcaemia, Hypogonadism, Hypopituitarism, Hypothyroidism, Liver disease, Nonalcoholic steatohepatitis (NASH), Lysosomal storage disorders, Nutrition and vitamins, Rickets, Pheochromocytoma, Primary bilary cirrhosis, Prolactinemia, Short stature, Syndrome of Inappropriate Antidiuretic Hormone (SIADH), Thyroid disease, plus other metabolic indications.

In ‘Global Metabolic Partnering 2010 to 2016’, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Metabolic Partnering 2010-2016’ report provides comprehensive access to available deals and contract documents for over 1,000 metabolic deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Metabolic Partnering 2010 to 2016’ provides the reader with the following key benefits:

  • In-depth understanding of Metabolic deal trends since 2010
  • Access Metabolic deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Metabolic partner companies
  • Comprehensive access to over 750 links to actual Metabolic deals entered into by the world's biopharma companies
  • Indepth review of Metabolic deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Metabolic opportunities
  • Uncover companies actively partnering Metabolic opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Metabolic dealmaking

  • 2.1. Introduction
  • 2.2. Metabolic partnering over the years
  • 2.3. Metabolic partnering by deal type
  • 2.4. Metabolic partnering by industry sector
  • 2.5. Metabolic partnering by stage of development
  • 2.6. Metabolic partnering by technology type
  • 2.7. Metabolic partnering by therapeutic indication

Chapter 3 -Financial deal terms for Metabolic partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Metabolic partnering
  • 3.3. Metabolic partnering headline values
  • 3.4. Metabolic deal upfront payments
  • 3.5. Metabolic deal milestone payments
  • 3.6. Metabolic royalty rates

Chapter 4 - Leading Metabolic deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Metabolic partnering
  • 4.3. List of most active dealmakers in Metabolic
  • 4.4. Top Metabolic deals by value

Chapter 5 - Metabolic contract document directory

  • 5.1. Introduction
  • 5.2. Metabolic partnering deals where contract document available

Chapter 6 - Metabolic dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Metabolic therapeutic target

Appendices

  • Appendix 1 - Directory of Metabolic deals by company A-Z 2010 to 2016
  • Appendix 2 - Directory of Metabolic deals by deal type 2010 to 2016
  • Appendix 3 - Directory of Metabolic deals by stage of development 2010 to 2016
  • Appendix 4 - Directory of Metabolic deals by technology type 2010 to 2016
  • Further reading on dealmaking
  • Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Metabolic partnering since 2010
  • Figure 2: Metabolic partnering by deal type since 2010
  • Figure 3: Metabolic partnering by industry sector since 2010
  • Figure 4: Metabolic partnering by stage of development since 2010
  • Figure 5: Metabolic partnering by technology type since 2010
  • Figure 6: Metabolic partnering by indication since 2010
  • Figure 7: Metabolic deals with a headline value
  • Figure 8: Metabolic deals with upfront payment values
  • Figure 9: Metabolic deals with milestone payment
  • Figure 10: Metabolic deals with royalty rates
  • Figure 11: Active Metabolic dealmaking activity- 2010 to 2016
  • Figure 12: Top Metabolic deals by value since 2010
Back to Top